Portal de Periódicos da CAPES

Proton‐pump Inhibitor Response Prediction Using Esophageal microRNAs in Children With Eosinophilic Esophagitis

2020; Lippincott Williams & Wilkins; Volume: 71; Issue: 6 Linguagem: Inglês

10.1097/mpg.0000000000002957

1536-4801

J. A. Cañas, Ana Tabares, Claudia Barbero, Daniel García‐Sánchez, Beatriz Sastre, José M. Rodrigo‐Muñoz, Ignacio Mahíllo, Ana Rayo, Belén Borrell, M L Cilleruelo, Enriqueta Román, Sonia Fernández‐Fernández, Carolina Gutiérrez‐Junquera, Victoria del Pozo,

IL-33, ST2, and ILC Pathways

ABSTRACT Objectives: Eosinophilic esophagitis (EoE) is a chronic esophageal disease characterized by eosinophilic inflammation. Proton‐pump inhibitors (PPI) induce disease remission but no predictive factors of PPI‐responsiveness have been identified yet. So, a biomarker must be found to differentiate between responders (PPI‐R) and nonresponder patients (PPI‐NR) to PPI. Aims were to identify any molecular biomarker that could predict PPI responsiveness and to study molecular remission after PPI therapy. Methods: This prospective study enrolled 39 controls and 43 pediatric children with EoE from 2 hospitals, and they were treated with esomeprazole for 8 to 12 weeks. After therapy, patients were classified as either PPI‐R or PPI‐NR. Biopsies were collected and RNA, microRNAs, and proteins were isolated from them, measuring levels by qPCR and Western blot (WB). Also, miRNAs were evaluated in serum. Results: We found several esophageal miRNAs with different expression values between PPI‐R and PPI‐NR children, which can be used to discriminate them (area under curve = 0.90). No useful serum miRNAs were, however, identified. Also, these miRNAs were dysregulated in responder patients before and after PPI therapy. Moreover, we corroborated in this child population, that PPI‐R displayed a significant decrease in eotaxin‐3, IL‐5, IL‐13, periostin, and major basic protein ( P < 0.05) and a significant increase in filaggrin levels after PPI treatment ( P < 0.01). Conclusions: Esophageal miRNA levels found are able to discriminate between both PPI‐R and PPI‐NR at baseline, and before and after treatment in PPI‐R, so they could be used as biomarkers. Furthermore, we observed clinical and esophageal molecular restoration in PPI‐R patients after PPI therapy.